| Description | Bifidobacterium is Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In Bifidobacterium is Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS.... Read More | Bifidobacterium is Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In Bifidobacterium is Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS.... Read More | Creative Biolabs offers the overexpression cell line which expressing the co-inhibitory and co-stimulatory immune checkpoints of human, mouse and cynomolgus monkey origin to accelerate immunotherapy discovery and development. | This product is a 38.6 kDa Human GPR20 membrane protein expressed in HEK293. The protein is for research use only and is not approved for use in humans or in clinical diagnosis. | The product SIRGT73619WQ-2MOE is a type of small interfering RNA (siRNA) that targets PET100 gene and regulates the expression of gene. The siRNA interferes with the expression of PET100 gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The The product SIRGT73619WQ-2MOE is a type of small interfering RNA (siRNA) that targets PET100 gene and regulates the expression of gene. The siRNA interferes with the expression of PET100 gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNA is designed with 2'-O-methoxyethyl (2'-MOE) modification to provide increased stability, increased specificity and reduced immunogenicity. It has potential applications in RNA interference (RNAi) and gene therapy development.... Read More |